QXO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BUY now for a tactical rebound setup. QXO is trading at 22.32 (-2.04%) and is pressing into a key support zone (S1 22.619 / S2 22.112) while short-term momentum is washed out (RSI-6 ~25.9). Options positioning is clearly risk-on (put/call ratios low), and Wall Street remains broadly bullish with most targets clustered around 30–31, implying meaningful upside if the market gets any M&A confirmation. I’d buy here expecting a bounce back toward the 23.44 pivot first, then 24.26 if momentum stabilizes.
Trend/Momentum: Bearish near-term trend remains in force (MACD histogram -0.333 and worsening), indicating downside momentum is still expanding. Mean-reversion setup: RSI_6 ~25.936 indicates the stock is stretched/oversold on a short lookback, which often supports a near-term bounce even if the bigger trend is soft. Levels: Current 22.32 is below the 23.441 pivot and sitting between S1 22.619 and S2 22.112. This is a critical decision area: holding above ~22.11 favors a rebound toward 23.44 (pivot) and then 24.26 (R1). A clean break below ~22.11 would undermine the bounce thesis. Moving averages: Converging MAs suggest the stock may be nearing an inflection, but price action still needs to reclaim the pivot to confirm stabilization. Pattern stats (similar candlesticks): Model indicates upside bias: ~80% chance of +1.39% next day, +3.74% next week, +4.67% next month.
Intellectia Proprietary Trading Signals
Event-driven upside optionality: Multiple analysts highlight expectation for sizable incremental M&A; any confirmed deal could re-rate the stock.
Street support: Predominantly Buy/Outperform ratings with targets mostly around 30–31 (well above 22.32).
Technical setup: Price is sitting at major support (22.11–22.
with short-term oversold readings, supporting a rebound attempt.
Upcoming earnings: QDEC 2025 earnings on 2026-02-26 (after hours) can act as a catalyst if results/forward commentary improve.
Momentum is still negative: MACD is below zero and deteriorating, so the down-move isn’t fully exhausted.
Macro/industry headwinds: Analysts note housing affordability/rates, mixed nonresidential demand, tariffs/policy uncertainty, and R&R weakness.
Execution risk: The bull thesis leans heavily on additional M&A; delays or unattractive deal terms could disappoint.
No fresh news this week: Lack of near-term headlines may keep the stock drifting until earnings or an M&A update.
Latest provided quarter: 2024/Q3. Growth/read-through: Revenue was essentially flat YoY (0.00% reported). Profitability remains weak with net income still negative (-5.368M) and EPS at -0.01 (also shown as 0.00% YoY change). Gross margin is high at ~39.51%, but the snapshot doesn’t show accelerating top-line growth—supporting the view that the next leg up is more catalyst/M&A-driven than organic-growth-driven.
Recent trend: Price targets were trimmed by several firms in early Jan (RBC to $30 from $33; Citi to $31 from $33; Truist to $26 from $28), reflecting near-term demand/macro caution. However, ratings remain positive (Buy/Outperform), and Oppenheimer raised its target to $30 (from $27) on 2026-01-16. Wall Street pros: Broadly bullish on strategic upside and consolidation/M&A potential (Beacon platform cited as durable; runway for industry consolidation). Wall Street cons: Near-term end-market softness (R&R weakness, limited storm activity), policy/rate/tariff risks, and volatility; some estimates were reduced on softer channel checks. Influential buying/selling: Hedge funds and insiders are reported Neutral with no significant recent trend; no recent Congress trading data available.
